News Immatics N.V.

Equities

Market Closed - Nasdaq Other stock markets 21:30:01 03/05/2024 BST			5-day change	1st Jan Change
10.77 ^USD	-1.10%		+7.59%	+2.28%

04-17	Certain Ordinary Shares of Immatics N.V. are subject to a Lock-Up Agreement Ending on 17-APR-2024.	CI
04-17	Certain Warrants of Immatics N.V. are subject to a Lock-Up Agreement Ending on 17-APR-2024.	CI

Certain Ordinary Shares of Immatics N.V. are subject to a Lock-Up Agreement Ending on 17-APR-2024.	04-16	CI
Certain Warrants of Immatics N.V. are subject to a Lock-Up Agreement Ending on 17-APR-2024.	04-16	CI
Certain Options of Immatics N.V. are subject to a Lock-Up Agreement Ending on 17-APR-2024.	04-16	CI
Sector Update: Health Care Stocks Gain Pre-Bell Thursday	03-21	MT
Sector Update: Health Care	03-21	MT
Immatics Swings to 2023 Net Loss, Revenue Falls -- Shares Down Pre-Bell	03-21	MT
Immatics N.V. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
Immatics N : Corporate Presentation March 2024	03-21	PU
Immatics Announces Full Year 2023 Financial Results and Corporate Update	03-21	GL
Sector Update: Health Care Stocks Mixed Premarket Thursday	01-18	MT
Immatics Prices $175 Million Share Offering	01-18	MT
Immatics Announces Pricing of $175 Million Public Offering	01-18	GL
Immatics Announces Pricing of $175 Million Public Offering	01-18	AQ
Immatics Plans Common Stock Offering	01-17	MT
Immatics Announces Proposed Public Offering	01-17	GL
Immatics Announces Proposed Public Offering	01-17	AQ
Immatics: Q3 Earnings Snapshot	11-14	AQ
Immatics N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Immatics Announces Third Quarter 2023 Financial Results and Business Update	11-14	GL
Immatics Reports Interim Clinical Data from ACTengine IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial	11-09	AQ

No results for this search